Vertex Pharmaceuticals (VRTX) Short-Term Debt issuances (2017)

Vertex Pharmaceuticals (VRTX) posted quarterly Short-Term Debt issuances of $300.0 million for Q1 2017.

Vertex Pharmaceuticals (VRTX) Short-Term Debt issuances (2017) Analysis & Trends

Vertex Pharmaceuticals' Short-Term Debt issuances history runs 1 years deep, the most recent figure standing at $300.0 million for Q1 2017.

In Q1 2017, Short-Term Debt issuances changed N/A year-over-year to $300.0 million; the TTM figure through Dec 2017 stood at $300.0 million (changed N/A YoY), while the FY2017 annual figure was $300.0 million, changed N/A from the prior year.
Short-Term Debt issuances for Q1 2017 stood at $300.0 million.
The five-year high for Short-Term Debt issuances was $300.0 million in Q1 2017, with the low at $300.0 million in Q1 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Short-Term Debt issuances (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Roivant Sciences	26.16 Bn	26.85 Bn	1.16 Mn	-

Download Data

Date	Value
Mar 31, 2017	300.00 Mn
Mar 31, 2017	300.00 Mn